Early Detection Of Alpha-Synuclein Disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Possible prodromal synucleinopathy
    2. Diagnosis of Parkinson´s disease (PD), Lewy Body Dementia (DLB), Multiple System Atrophy (MSA)
    3. Adult (age = 18) men and women who are ambulatory and functionally independent and able to provide appropriate consent as determined by screening study physician
    4. Willingness to participate in study procedures (skin biopsy)

You may not be eligible for this study if the following are true:

    1. Existing diagnosis or evidence of advanced neurodegenerative disorder
    2. Unstable psychiatric illness, including psychosis, suicidal ideation, or untreated major depression within 90 days before Initial Visit, as determined by investigator
    3. History or baseline MRI results showing evidence of structural abnormalities that could contribute to the participant’s clinical state, or any finding that might pose a risk to the participant
    4. Major coexisting disability or medical condition that would prevent accurate assessment or prevent safe participation in study tasks, including peripheral neuropathy secondary to diabetes mellitus, amyloidosis, paraneoplasic syndrome, neurotoxin-induced or other causes
    5. History of any brain surgery for movement disorders (e.g., pallidotomy, deep brain stimulation, or fetal tissue transplant) or a history of focused ultrasound treatment or neuromodulation procedures.
    6. Participants with abnormal coagulation results (PT/INR, aPTT)
    7. History of human immunodeficiency virus or hepatitis C virus antibody.
    8. Chronic, recurrent, or serious infection
    9. History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class 3 or 4), or clinically significant conduction abnormalities
    10. History of, or ongoing, malignant disease
    11. History of any clinically significant endocrinological, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, ischemic, or other major diseases
    12. Clinically significant allergies
    13. Participation in a clinical trial testing potential investigational disease-modifying drug
    14. Unwillingness or inability to comply with the requirements of this protocol.
    15. Other unspecified reasons that, in the clinical opinion of the Investigator, make the participant unsuitable for enrollment

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.